The global HER-2 Targeted Drugs for Breast Cancer market size was valued at US$ 11.23 billion in 2024 and is projected to reach US$ 17.56 billion by 2030, at a CAGR of 7.7% during the forecast period 2024-2030.
United States HER-2 Targeted Drugs for Breast Cancer market size was valued at US$ 5.67 billion in 2024 and is projected to reach US$ 8.73 billion by 2030, at a CAGR of 7.4% during the forecast period 2024-2030.
Drugs specifically targeting the HER-2 protein, which is overexpressed in some breast cancers, including monoclonal antibodies and tyrosine kinase inhibitors.
Rapid growth supported by expanding indications and combination therapies. Development of novel HER-2 targeted agents enhancing market potential. Increasing use in early-stage and metastatic settings driving market expansion.
Report Overview
This report provides a deep insight into the global Targeted Drugs for Breast Cancer market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Targeted Drugs for Breast Cancer Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Targeted Drugs for Breast Cancer market in any manner.
Global Targeted Drugs for Breast Cancer Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
- Roche
- Teva
- Mylan
- Hikma
- Hengrui Medicine
- Cipla
- Reliance Group
- Hetero
- Pfizer
- Eli Lilly
- Novartis
- CANbridge
- Puma Biotechnology
- AstraZeneca
- Chugai Pharmaceutical
- Eisai
- GlaxoSmithKline
- Bristol-Myers Squibb
- Otsuka Pharmaceutical
- Merck
- BioMarin
- Hengrui Pharmaceutical
- Beijing Biostar Technologies
- Bayer
Market Segmentation (by Type)
- HER-2 Targeted Drugs
- CDK4/6 Inhibitors
- PARP Targeted Drugs
- PI3K/AKT/mTor Pathway Inhibitors
- ER Targeted Drugs
- Aromatase Inhibitors
- Tubulin Inhibitors
- VEGF Targeted Drugs
- YTMS Targeted Drugs
- Other
- by Application
Market Segmentation (by Application)
- Hospital
- Clinic
- Drug Center
- Other
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Targeted Drugs for Breast Cancer Market
- Overview of the regional outlook of the Targeted Drugs for Breast Cancer Market:
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value (USD Billion) data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the
major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of HER-2 Targeted Drugs for Breast Cancer
1.2 Key Market Segments
1.2.1 HER-2 Targeted Drugs for Breast Cancer Segment by Type
1.2.2 HER-2 Targeted Drugs for Breast Cancer Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 HER-2 Targeted Drugs for Breast Cancer Market Overview
2.1 Global Market Overview
2.1.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global HER-2 Targeted Drugs for Breast Cancer Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 HER-2 Targeted Drugs for Breast Cancer Market Competitive Landscape
3.1 Global HER-2 Targeted Drugs for Breast Cancer Sales by Manufacturers (2019-2024)
3.2 Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Manufacturers (2019-2024)
3.3 HER-2 Targeted Drugs for Breast Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global HER-2 Targeted Drugs for Breast Cancer Average Price by Manufacturers (2019-2024)
3.5 Manufacturers HER-2 Targeted Drugs for Breast Cancer Sales Sites, Area Served, Product Type
3.6 HER-2 Targeted Drugs for Breast Cancer Market Competitive Situation and Trends
3.6.1 HER-2 Targeted Drugs for Breast Cancer Market Concentration Rate
3.6.2 Global 5 and 10 Largest HER-2 Targeted Drugs for Breast Cancer Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 HER-2 Targeted Drugs for Breast Cancer Industry Chain Analysis
4.1 HER-2 Targeted Drugs for Breast Cancer Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of HER-2 Targeted Drugs for Breast Cancer Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 HER-2 Targeted Drugs for Breast Cancer Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Type (2019-2024)
6.3 Global HER-2 Targeted Drugs for Breast Cancer Market Size Market Share by Type (2019-2024)
6.4 Global HER-2 Targeted Drugs for Breast Cancer Price by Type (2019-2024)
7 HER-2 Targeted Drugs for Breast Cancer Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global HER-2 Targeted Drugs for Breast Cancer Market Sales by Application (2019-2024)
7.3 Global HER-2 Targeted Drugs for Breast Cancer Market Size (M USD) by Application (2019-2024)
7.4 Global HER-2 Targeted Drugs for Breast Cancer Sales Growth Rate by Application (2019-2024)
8 HER-2 Targeted Drugs for Breast Cancer Market Segmentation by Region
8.1 Global HER-2 Targeted Drugs for Breast Cancer Sales by Region
8.1.1 Global HER-2 Targeted Drugs for Breast Cancer Sales by Region
8.1.2 Global HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Region
8.2 North America
8.2.1 North America HER-2 Targeted Drugs for Breast Cancer Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe HER-2 Targeted Drugs for Breast Cancer Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific HER-2 Targeted Drugs for Breast Cancer Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America HER-2 Targeted Drugs for Breast Cancer Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Roche
9.1.1 Roche HER-2 Targeted Drugs for Breast Cancer Basic Information
9.1.2 Roche HER-2 Targeted Drugs for Breast Cancer Product Overview
9.1.3 Roche HER-2 Targeted Drugs for Breast Cancer Product Market Performance
9.1.4 Roche Business Overview
9.1.5 Roche HER-2 Targeted Drugs for Breast Cancer SWOT Analysis
9.1.6 Roche Recent Developments
9.2 Chugai Pharmaceutical
9.2.1 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Basic Information
9.2.2 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Product Overview
9.2.3 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Product Market Performance
9.2.4 Chugai Pharmaceutical Business Overview
9.2.5 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer SWOT Analysis
9.2.6 Chugai Pharmaceutical Recent Developments
9.3 GlaxoSmithKline
9.3.1 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Basic Information
9.3.2 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Product Overview
9.3.3 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Product Market Performance
9.3.4 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer SWOT Analysis
9.3.5 GlaxoSmithKline Business Overview
9.3.6 GlaxoSmithKline Recent Developments
9.4 Novartis
9.4.1 Novartis HER-2 Targeted Drugs for Breast Cancer Basic Information
9.4.2 Novartis HER-2 Targeted Drugs for Breast Cancer Product Overview
9.4.3 Novartis HER-2 Targeted Drugs for Breast Cancer Product Market Performance
9.4.4 Novartis Business Overview
9.4.5 Novartis Recent Developments
9.5 Pfizer
9.5.1 Pfizer HER-2 Targeted Drugs for Breast Cancer Basic Information
9.5.2 Pfizer HER-2 Targeted Drugs for Breast Cancer Product Overview
9.5.3 Pfizer HER-2 Targeted Drugs for Breast Cancer Product Market Performance
9.5.4 Pfizer Business Overview
9.5.5 Pfizer Recent Developments
9.6 CANbridge
9.6.1 CANbridge HER-2 Targeted Drugs for Breast Cancer Basic Information
9.6.2 CANbridge HER-2 Targeted Drugs for Breast Cancer Product Overview
9.6.3 CANbridge HER-2 Targeted Drugs for Breast Cancer Product Market Performance
9.6.4 CANbridge Business Overview
9.6.5 CANbridge Recent Developments
9.7 Puma Biotechnology
9.7.1 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Basic Information
9.7.2 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Product Overview
9.7.3 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Product Market Performance
9.7.4 Puma Biotechnology Business Overview
9.7.5 Puma Biotechnology Recent Developments
9.8 Hengrui Medicine
9.8.1 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Basic Information
9.8.2 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Product Overview
9.8.3 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Product Market Performance
9.8.4 Hengrui Medicine Business Overview
9.8.5 Hengrui Medicine Recent Developments
9.9 Beacon Pharmaceuticals Limited
9.9.1 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Basic Information
9.9.2 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Product Overview
9.9.3 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Product Market Performance
9.9.4 Beacon Pharmaceuticals Limited Business Overview
9.9.5 Beacon Pharmaceuticals Limited Recent Developments
9.10 Hetero Drugs
9.10.1 Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Basic Information
9.10.2 Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Product Overview
9.10.3 Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Product Market Performance
9.10.4 Hetero Drugs Business Overview
9.10.5 Hetero Drugs Recent Developments
10 HER-2 Targeted Drugs for Breast Cancer Market Forecast by Region
10.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size Forecast
10.2 Global HER-2 Targeted Drugs for Breast Cancer Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Country
10.2.3 Asia Pacific HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Region
10.2.4 South America HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of HER-2 Targeted Drugs for Breast Cancer by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global HER-2 Targeted Drugs for Breast Cancer Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of HER-2 Targeted Drugs for Breast Cancer by Type (2025-2030)
11.1.2 Global HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of HER-2 Targeted Drugs for Breast Cancer by Type (2025-2030)
11.2 Global HER-2 Targeted Drugs for Breast Cancer Market Forecast by Application (2025-2030)
11.2.1 Global HER-2 Targeted Drugs for Breast Cancer Sales (K Units) Forecast by Application
11.2.2 Global HER-2 Targeted Drugs for Breast Cancer Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. HER-2 Targeted Drugs for Breast Cancer Market Size Comparison by Region (M USD)
Table 5. Global HER-2 Targeted Drugs for Breast Cancer Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Manufacturers (2019-2024)
Table 7. Global HER-2 Targeted Drugs for Breast Cancer Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global HER-2 Targeted Drugs for Breast Cancer Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HER-2 Targeted Drugs for Breast Cancer as of 2022)
Table 10. Global Market HER-2 Targeted Drugs for Breast Cancer Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers HER-2 Targeted Drugs for Breast Cancer Sales Sites and Area Served
Table 12. Manufacturers HER-2 Targeted Drugs for Breast Cancer Product Type
Table 13. Global HER-2 Targeted Drugs for Breast Cancer Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of HER-2 Targeted Drugs for Breast Cancer
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. HER-2 Targeted Drugs for Breast Cancer Market Challenges
Table 22. Global HER-2 Targeted Drugs for Breast Cancer Sales by Type (K Units)
Table 23. Global HER-2 Targeted Drugs for Breast Cancer Market Size by Type (M USD)
Table 24. Global HER-2 Targeted Drugs for Breast Cancer Sales (K Units) by Type (2019-2024)
Table 25. Global HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Type (2019-2024)
Table 26. Global HER-2 Targeted Drugs for Breast Cancer Market Size (M USD) by Type (2019-2024)
Table 27. Global HER-2 Targeted Drugs for Breast Cancer Market Size Share by Type (2019-2024)
Table 28. Global HER-2 Targeted Drugs for Breast Cancer Price (USD/Unit) by Type (2019-2024)
Table 29. Global HER-2 Targeted Drugs for Breast Cancer Sales (K Units) by Application
Table 30. Global HER-2 Targeted Drugs for Breast Cancer Market Size by Application
Table 31. Global HER-2 Targeted Drugs for Breast Cancer Sales by Application (2019-2024) & (K Units)
Table 32. Global HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Application (2019-2024)
Table 33. Global HER-2 Targeted Drugs for Breast Cancer Sales by Application (2019-2024) & (M USD)
Table 34. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Application (2019-2024)
Table 35. Global HER-2 Targeted Drugs for Breast Cancer Sales Growth Rate by Application (2019-2024)
Table 36. Global HER-2 Targeted Drugs for Breast Cancer Sales by Region (2019-2024) & (K Units)
Table 37. Global HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Region (2019-2024)
Table 38. North America HER-2 Targeted Drugs for Breast Cancer Sales by Country (2019-2024) & (K Units)
Table 39. Europe HER-2 Targeted Drugs for Breast Cancer Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific HER-2 Targeted Drugs for Breast Cancer Sales by Region (2019-2024) & (K Units)
Table 41. South America HER-2 Targeted Drugs for Breast Cancer Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Sales by Region (2019-2024) & (K Units)
Table 43. Roche HER-2 Targeted Drugs for Breast Cancer Basic Information
Table 44. Roche HER-2 Targeted Drugs for Breast Cancer Product Overview
Table 45. Roche HER-2 Targeted Drugs for Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Roche Business Overview
Table 47. Roche HER-2 Targeted Drugs for Breast Cancer SWOT Analysis
Table 48. Roche Recent Developments
Table 49. Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Basic Information
Table 50. Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Product Overview
Table 51. Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Chugai Pharmaceutical Business Overview
Table 53. Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer SWOT Analysis
Table 54. Chugai Pharmaceutical Recent Developments
Table 55. GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Basic Information
Table 56. GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Product Overview
Table 57. GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer SWOT Analysis
Table 59. GlaxoSmithKline Business Overview
Table 60. GlaxoSmithKline Recent Developments
Table 61. Novartis HER-2 Targeted Drugs for Breast Cancer Basic Information
Table 62. Novartis HER-2 Targeted Drugs for Breast Cancer Product Overview
Table 63. Novartis HER-2 Targeted Drugs for Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Novartis Business Overview
Table 65. Novartis Recent Developments
Table 66. Pfizer HER-2 Targeted Drugs for Breast Cancer Basic Information
Table 67. Pfizer HER-2 Targeted Drugs for Breast Cancer Product Overview
Table 68. Pfizer HER-2 Targeted Drugs for Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Pfizer Business Overview
Table 70. Pfizer Recent Developments
Table 71. CANbridge HER-2 Targeted Drugs for Breast Cancer Basic Information
Table 72. CANbridge HER-2 Targeted Drugs for Breast Cancer Product Overview
Table 73. CANbridge HER-2 Targeted Drugs for Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. CANbridge Business Overview
Table 75. CANbridge Recent Developments
Table 76. Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Basic Information
Table 77. Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Product Overview
Table 78. Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Puma Biotechnology Business Overview
Table 80. Puma Biotechnology Recent Developments
Table 81. Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Basic Information
Table 82. Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Product Overview
Table 83. Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Hengrui Medicine Business Overview
Table 85. Hengrui Medicine Recent Developments
Table 86. Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Basic Information
Table 87. Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Product Overview
Table 88. Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Beacon Pharmaceuticals Limited Business Overview
Table 90. Beacon Pharmaceuticals Limited Recent Developments
Table 91. Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Basic Information
Table 92. Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Product Overview
Table 93. Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Hetero Drugs Business Overview
Table 95. Hetero Drugs Recent Developments
Table 96. Global HER-2 Targeted Drugs for Breast Cancer Sales Forecast by Region (2025-2030) & (K Units)
Table 97. Global HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Region (2025-2030) & (M USD)
Table 98. North America HER-2 Targeted Drugs for Breast Cancer Sales Forecast by Country (2025-2030) & (K Units)
Table 99. North America HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Country (2025-2030) & (M USD)
Table 100. Europe HER-2 Targeted Drugs for Breast Cancer Sales Forecast by Country (2025-2030) & (K Units)
Table 101. Europe HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Country (2025-2030) & (M USD)
Table 102. Asia Pacific HER-2 Targeted Drugs for Breast Cancer Sales Forecast by Region (2025-2030) & (K Units)
Table 103. Asia Pacific HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Region (2025-2030) & (M USD)
Table 104. South America HER-2 Targeted Drugs for Breast Cancer Sales Forecast by Country (2025-2030) & (K Units)
Table 105. South America HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Country (2025-2030) & (M USD)
Table 106. Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Consumption Forecast by Country (2025-2030) & (Units)
Table 107. Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Country (2025-2030) & (M USD)
Table 108. Global HER-2 Targeted Drugs for Breast Cancer Sales Forecast by Type (2025-2030) & (K Units)
Table 109. Global HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Type (2025-2030) & (M USD)
Table 110. Global HER-2 Targeted Drugs for Breast Cancer Price Forecast by Type (2025-2030) & (USD/Unit)
Table 111. Global HER-2 Targeted Drugs for Breast Cancer Sales (K Units) Forecast by Application (2025-2030)
Table 112. Global HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Application (2025-2030) & (M USD)
List of Figures
Figure 1. Product Picture of HER-2 Targeted Drugs for Breast Cancer
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global HER-2 Targeted Drugs for Breast Cancer Market Size (M USD), 2019-2030
Figure 5. Global HER-2 Targeted Drugs for Breast Cancer Market Size (M USD) (2019-2030)
Figure 6. Global HER-2 Targeted Drugs for Breast Cancer Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. HER-2 Targeted Drugs for Breast Cancer Market Size by Country (M USD)
Figure 11. HER-2 Targeted Drugs for Breast Cancer Sales Share by Manufacturers in 2023
Figure 12. Global HER-2 Targeted Drugs for Breast Cancer Revenue Share by Manufacturers in 2023
Figure 13. HER-2 Targeted Drugs for Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market HER-2 Targeted Drugs for Breast Cancer Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by HER-2 Targeted Drugs for Breast Cancer Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Type
Figure 18. Sales Market Share of HER-2 Targeted Drugs for Breast Cancer by Type (2019-2024)
Figure 19. Sales Market Share of HER-2 Targeted Drugs for Breast Cancer by Type in 2023
Figure 20. Market Size Share of HER-2 Targeted Drugs for Breast Cancer by Type (2019-2024)
Figure 21. Market Size Market Share of HER-2 Targeted Drugs for Breast Cancer by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Application
Figure 24. Global HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Application (2019-2024)
Figure 25. Global HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Application in 2023
Figure 26. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Application (2019-2024)
Figure 27. Global HER-2 Targeted Drugs for Breast Cancer Market Share by Application in 2023
Figure 28. Global HER-2 Targeted Drugs for Breast Cancer Sales Growth Rate by Application (2019-2024)
Figure 29. Global HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Region (2019-2024)
Figure 30. North America HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Country in 2023
Figure 32. U.S. HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada HER-2 Targeted Drugs for Breast Cancer Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico HER-2 Targeted Drugs for Breast Cancer Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Country in 2023
Figure 37. Germany HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (K Units)
Figure 43. Asia Pacific HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Region in 2023
Figure 44. China HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (K Units)
Figure 50. South America HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Country in 2023
Figure 51. Brazil HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Region in 2023
Figure 56. Saudi Arabia HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa HER-2 Targeted Drugs for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global HER-2 Targeted Drugs for Breast Cancer Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global HER-2 Targeted Drugs for Breast Cancer Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global HER-2 Targeted Drugs for Breast Cancer Market Share Forecast by Type (2025-2030)
Figure 65. Global HER-2 Targeted Drugs for Breast Cancer Sales Forecast by Application (2025-2030)
Figure 66. Global HER-2 Targeted Drugs for Breast Cancer Market Share Forecast by Application (2025-2030)
